Prescription medicine
Nepafenac Brand names: Ilevro, Nevanac
Nepafenac (Ilevro) is a prescription medicine with an FDA approval on record since 2005. No generic is listed; pharmacies paid $121.14 per mL (Ilevro 0.3% eye drops) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the nepafenac FDA label on DailyMed (effective April 1, 2026, Harrow Eye, LLC); the NDA 21862 record on Drugs@FDA; every nepafenac label on DailyMed.
Highlights of the record
FDA label of April 1, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.
Forms and strengths
- 1 mg/ml
- 3 mg/ml
Suspension/ drops.
On the market
- Earliest approval on file
- August 19, 2005 Nevanac, Harrow Eye; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- March 31, 2032 Ilevro suspension/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $121.14 per mL Ilevro 0.3% eye drops
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 3,181 through July 30, 2026
What is nepafenac used for?
From the label: indications and usageILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).
Conditions named in the indications of nepafenac's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Nonsteroidal Anti-inflammatory Drug.
Source: FDA drug label (ILEVRO), Harrow Eye, LLC, effective April 1, 2026 (SPL set 10f411d3-a81e-074a-e063-6294a90ab547), via openFDA; the full label on DailyMed
Is there a generic for nepafenac (Ilevro)?
No generic nepafenac is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 2 patents for Ilevro suspension/drops, the last expiring on March 31, 2032. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2005 earliest approval on file
- 2032 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for nepafenac (Ilevro)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $121.14 per mL (Ilevro 0.3% eye drops), about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Nevanac 0.1% eye drop (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ilevro 0.3% eye drops | Brand | $121.14 per mL | n/a | +0.1% |
| Nevanac 0.1% eye drop | Brand | $104.71 per mL | n/a | -0.4% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for nepafenac?
The FDA Adverse Event Reporting System holds 3,181 reports that list nepafenac among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 74 are coded as a death and 375 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as nepafenac?
4 other medicines are given the same way (ophthalmic) and in the same FDA class as nepafenac or labeled mainly for the same use (pain), the same class first. Pain lists all 80 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ketorolac | Pain | 17 labelers | $1.39 per mL 0.5% eye solution | In shortage |
| Bromfenac | Pain | 9 labelers | $13.25 per mL 0.07% eye drp | No current entry |
| Diclofenac | Pain | 5 labelers | $1.70 per mL 0.1% eye drops | A presentation being discontinued |
| Loteprednol | Pain | 8 labelers | $10.47 per mL 0.5% drp | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to nepafenac
- 4 medicines for the same use
- Other NSAIDs
- the pharmacologic class, with prices and generics
- Nepafenac side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other